Eli Lilly and Company Reports Q3 2025 Financial Results and Raises 2025 Guidance
Summary
Eli Lilly and Company announced its financial results for the quarter ended September 30, 2025, via Ex. 99.1 press release dated October 30, 2025. The company reported a 54% increase in Q3 2025 revenue to $17.60 billion, primarily driven by volume growth from Mounjaro and Zepbound. Reported EPS for Q3 2025 rose by $5.14 to $6.21, with non-GAAP EPS increasing by $5.84 to $7.02. * Increased 2025 full-year revenue guidance to $63.0 billion - $63.5 billion. * Raised reported EPS guidance to $21.80 - $22.50 and non-GAAP EPS to $23.00 - $23.70. * Positive Phase 3 results for orforglipron across type 2 diabetes and obesity, with regulatory submission for obesity planned by year-end. * U.S. FDA approval of Inluriyo (imlunestrant) for certain advanced or metastatic breast cancer.
Why It Matters
The significant 54% revenue increase to $17.60 billion, driven by key product volume growth, and the raised full-year 2025 guidance for both revenue and EPS, signal strong operational performance and a positive future outlook for investors.
These filing summaries are free and always will be. If this helped you spot material events, consider supporting us.
Want to see how LLY traded around this filing?
Check real-time charts and technical analysis on TradingView to see market reaction to this event.
View LLY Charts on TradingViewAffiliate link
Filing Details
Reported Items
Additional Information
- CIK Number
- 0000059478
- Filing Date
- Thursday, October 30, 2025
- Filing Time
- 12:00 AM UTC
- Form Type
- 8-K
- Materiality Level
- high
- Sentiment
- positive